Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL4: once-weekly somapacitan versus daily Norditropin in children with growth hormone deficiency
jRCT2080224698Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial in growth hormone deficiency (GHD) comparing Somapacitan once weekly with Norditropin daily (2 arms). Primary endpoint: Height velocity at week 52. Started May 2019; status: completed.
02
Drugs
somapacitansomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCT2080224698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224698.